Senti Biosciences Holdings (SNTI) Net Cash Flow (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Net Cash Flow of $4.2 million for Q4 2025, down 88.97% year-over-year from $37.8 million in Q4 2024, and up 144.68% quarter-over-quarter from -$9.3 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Net Cash Flow (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Net Cash Flow history runs 5 years deep, the most recent figure standing at $4.2 million for Q4 2025.
- In Q4 2025, Net Cash Flow fell 88.97% year-over-year to $4.2 million; the TTM figure through Dec 2025 stood at -$31.9 million (down 357.68% YoY), while the FY2025 annual figure was -$31.9 million, down 357.68% from the prior year.
- Net Cash Flow for Q4 2025 stood at $4.2 million, up from -$9.3 million in the prior quarter.
- The five-year high for Net Cash Flow was $101.7 million in Q2 2022, with the low at -$57.2 million in Q4 2022.
- The 5-year median for Net Cash Flow is -$6.4 million (2023), against an average of -$1.9 million.
- Peak annual rise in Net Cash Flow reached 9167.98% in 2022, while the deepest fall reached 6537.26% in 2022.
- Senti Biosciences Holdings' Net Cash Flow stood at $889323.0 in 2021, then plunged by 6537.26% to -$57.2 million in 2022, then surged by 88.86% to -$6.4 million in 2023, then jumped by 692.08% to $37.8 million in 2024, then slumped by 88.97% to $4.2 million in 2025.
- Business Quant data shows SNTI's Net Cash Flow at $4.2 million in Q4 2025, -$9.3 million in Q3 2025, and -$12.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.17 Mn |
| Dec 31, 2025 | 4.17 Mn |
| Sep 30, 2025 | -9.32 Mn |
| Sep 30, 2025 | -9.32 Mn |
| Jun 30, 2025 | -12.25 Mn |
| Jun 30, 2025 | -12.25 Mn |
| Mar 31, 2025 | -14.46 Mn |
| Mar 31, 2025 | -14.46 Mn |
| Dec 31, 2024 | 37.78 Mn |
| Dec 31, 2024 | 37.78 Mn |
| Sep 30, 2024 | -5.37 Mn |
| Sep 30, 2024 | -5.37 Mn |
| Jun 30, 2024 | -8.35 Mn |
| Jun 30, 2024 | -8.35 Mn |
| Mar 31, 2024 | -11.70 Mn |
| Mar 31, 2024 | -11.70 Mn |
| Dec 31, 2023 | -6.38 Mn |
| Dec 31, 2023 | -6.38 Mn |
| Sep 30, 2023 | 5.74 Mn |
| Sep 30, 2023 | 5.74 Mn |